Cynata said it had found a way of mass-producing mesenchymal stem cells (MSCs), which are being closely investigated for their applicability in treatments for various diseases.
Demonstrating that it can make cells at an industrial scale under Good Manufacturing Practice (GMP) protocols positions the Australian venture “at the forefront of regenerative medicine globally,” claimed the firm’s...